Treatment of cutaneous T-cell lymphoma with combined immunomodulatory therapy: a 14-year experience at a single institution.

Objective: To determine the efficacy of multimodality biologic response therapy for patients with cutaneous T-cell lymphoma (CTCL).

Design: Retrospective cohort study over a 14-year period.

Setting: Tertiary care university hospital.